



Angiogenesis and Anti-angiogenesis, Options for Treatment of Severe Disorders

Guest Editor:

Prof. Dr. Lars Norgren

Department of Surgery, Örebro
University, Örebro, Sweden

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editor

In addition to physiologic angiogenesis, leading to neovascularization and required for healing processes, the term “therapeutic angiogenesis” has been adopted in the search for treatment of ischemic conditions. On the other hand, since Folkman’s first publications in the early 1970s, the importance of anti-angiogenesis in cancer treatment has been evident. More recently, combinations of immune therapy and anti-angiogenetic treatment have been developed.

Regarding therapeutic angiogenesis with gene and cell therapy, various methods have been used in ischemic cardiovascular disease, including peripheral arterial disease, with varying results and without any evident breakthrough. A major issue is that treatment should not just induce arterio-/angiogenesis but also act on the inflammatory response that is part of ischemic pathology.

This Special Issue of *Biomedicines* invites papers in all areas of “Angiogenesis” as briefly summarized above.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI